Cybersecurity, life safety, patient privacy requirements among NFPA’s Health Care Facilities Code 2027 updates Facilities Dive
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
